www.synbio.org.uk

Synthetic Biology Resources at Cambridge

Compiled by Jim Haseloff at the University of Cambridge. SpannerPlantLogo140This site contains details of recent papers and activity in Synthetic Biology, with particular emphasis on: (i) development of standards in biology and DNA parts, (ii) microbial and (iii) plant systems, (iv) research and teaching in the field at the University of Cambridge, (v) hardware for scientific computing and instrumentation, (vi) tools for scientific productivity and collected miscellany.

Similar to the Cambridge-based Raspberry Pi and OpenLabTools initiatives, we promote the use of low cost and open source tools - in our case for use in biological engineering.

Google: synbio news

Run mouse over list to see previews, click for full article.

Twitter Feed

Recent News

IMAGE A Mitochondrial DNA Transplant Could Help Treat Hundreds Of Diseases
Thursday, 08 January 2015
For the first time ever, researchers in New Zealand have shown that mitochondrial DNA can move between cells in an animal tumor. It's an extraordinary finding that could lead to an entirely new field of synthetic biology and the treatment of hundreds of diseases. Read more... Read More...
IMAGE Impossibly imaginative food landscapes. Warning: don't look if hungry.
Thursday, 08 January 2015
" 'Processed Views,' a photography series by Barbara Ciurej and Lindsay Lochman.   From the artists:   Processed Views interprets the frontier of industrial food production: the seductive and alarming intersection of nature and technology. As we move further away from the sources of our food, we... Read More...
IMAGE This tiny button could solve the IoT’s big headache
Thursday, 08 January 2015
Controlling your digital life from your smartphone, or even by voice, is great, but there are times when it'd be a whole lot more convenient to reach out and stab a physical button. That's the idea behind Flic, crowdfunding success from late last year, and here at CES to show off what you can do... Read More...
IMAGE Intel’s “Compute Stick” is a full Windows or Linux PC in an HDMI dongle
Thursday, 08 January 2015
Andrew Cunningham The Intel Compute Stick is a full PC in an HDMI dongle. 3 more images in gallery // LAS VEGAS, NEVADA—Set-top boxes and streaming sticks are decent, cost-effective ways to turn the TV you already have into a 'smart TV,' but Intel has an intriguing new option for those of you... Read More...
IMAGE A microbe found in a grassy field appears to contain a remarkably powerful antibiotic.
Thursday, 08 January 2015
A microbe found in a grassy field appears to contain a remarkably powerful antibiotic. Called teixobactin, it kills dangerous pathogens without any observable resistance (at least not yet). Moreover, it destroys many types of drug-resistant bacteria and it's safe in mammals. Its use may be limited,... Read More...
IMAGE To Save Our Ecosystems, Will We Have to Design Synthetic Creatures?
Wednesday, 07 January 2015
To Save Our Ecosystems, Will We Have to Design Synthetic Creatures?BY LIZ STINSON   Imagine someday in the distant future, years after the ‘sixth extinction’ went from theory to undeniable reality. Our ecosystems are failing, our biodiversity is dropping like flies (at least the ones that... Read More...
Synthetic Biology Market worth $5,630.4 Million by 2018 - Major Market Players - Amyris, Inc. (U.S.), DuPont (U.S.), GenScript USA Inc. (U.S.), Intrexon Corporation (U.S.) - WhaTech
Wednesday, 07 January 2015
Synthetic Biology Market worth $5,630.4 Million by 2018 - Major Market Players - Amyris, Inc. (U.S.), DuPont (U.S.), GenScript USA Inc. (U.S.), Intrexon Corporation (U.S.) WhaTech Channel: Industrial Market Research Reports The global synthetic biology market is segmented on the basis of tools,... Read More...
IMAGE 3 Tech Giants Quietly Investing in Synthetic Biology (ADSK, INTC, MSFT)
Wednesday, 07 January 2015
3 Tech Giants Quietly Investing in Synthetic Biology By Maxx Chatsko | More Articles January 7, 2015 | Comments (0) The introduction and widespread adoption of fun new gadgets, games, and services in the last 15 years has provided billions of dollars of revenues and profits to the technology... Read More...

Featured News

This tiny button could solve the IoT’s big headache
Thursday, 08 January 2015
Controlling your digital life from your smartphone, or even by voice, is great, but there are times when it'd be a whole lot more convenient to reach out and stab a physical button. That's the idea behind Flic, crowdfunding success from late last year, and here at CES to show off what you can do with a tiny stick-on button, … Continue reading" 
Intel’s “Compute Stick” is a full Windows or Linux PC in an HDMI dongle
Thursday, 08 January 2015
Andrew Cunningham The Intel Compute Stick is a full PC in an HDMI dongle. 3 more images in gallery // LAS VEGAS, NEVADA—Set-top boxes and streaming sticks are decent, cost-effective ways to turn the TV you already have into a 'smart TV,' but Intel has an intriguing new option for those of you who want something a little more versatile. The Intel Compute Stick is a full Bay Trail PC complete... Read More...
Controlling a Flip-Disc Display Using Android
Thursday, 01 January 2015
There’s just something about electro-mechanical displays that enthralls most people when they see them; and while you’ll be hard pressed to find a split-flap display for cheap, you can still easily buy flip-disc displays! That’s what [Scott] did, and he’s been having a blast messing around with his and building a system to control it via his Android phone. He picked up the display from a... Read More...

Amyris info

Amyris Files to go Public—Biofuels from Microbes

BLOG REPORT FROM GREENTECHMEDIA by This email address is being protected from spambots. You need JavaScript enabled to view it.: APRIL 16, 2010

see http://www.greentechmedia.com/articles/read/amyris-files-to-go-public-biofuels-from-microbes/

In February, Michael Kanellos suggested that Amyris would be the next greentech startup to file to go public.  It pains me greatly to write that he was correct.

The synthetic biology firm, which has raisedmore than $244 million in private funding from Kleiner Perkins Caufield & Byers, Khosla Ventures, TPG Biotechnology, Advanced Equities, DAG Ventures, Grupo Cornélio Brennand, Naxos Capital Partners, The Westly Group, Stratus Group, and Temasek Holdings, et al. filed its SEC paperwork today and is looking to raise $100 million. 

 

Here's the link to the S-1.

The company, which was spun out of research conducted at UC Berkeley, feeds sugars to custom microbes which exude hydrocarbons to order which are then converted to fuels or industrial chemicals.   The CEO, John Melo, told Greentech Media in 2008 that $2 per gallon wholesale biodiesel was achievable.   According to the S-1, Melo made $408,333 in salary, $200,000 in bonus, and $221,617 in other compensation for a total of $829,950 in 2009.

The first product out of the company was an artificial version of artemisinin, an antimalaria drug that drew millions in support from the Bill and Melinda Gates Foundation.  


The company has been busy.  In December, it paid $82 million to Brazil's São Martinho Group for a 40-percent stake in an ethanol mill project that the parties hope will be operational by 2011 or 2012. The Brazilian company already controls three ethanol plants that make about 600 million liters (158 million gallons) of ethanol per year.   Soon after, it entered into agreements with three other Brazilian companies -- Acucar Guarani, Bunge Limited and Cosan -- to produce ethanol and high-value chemicals.  

Here are some tidbits from the SEC document:

Background

  • The company genetically modifies microorganisms, primarily yeast, and uses them as living factories in established fermentation processes to convert plant-sourced sugars into potentially thousands of target molecules. Their first commercialization efforts have been focused on a molecule called farnesene, the basis for a range of products varying from specialty chemical applications such as detergents, cosmetics, perfumes and industrial lubricants, to transportation fuels such as diesel. 
  • Amyris has developed genetic engineering and screening technologies that enable them to modify the way microorganisms, or microbes, process sugar. By controlling these metabolic pathways, the microbes serve as living factories, or biorefineries, to produce target molecules that the startup intends to commercialize. The platform utilizes proprietary high-throughput processes to create and test as many as 1,000 yeast strains a day in order to select those yeast strains which are most efficient. 
  • Amyris is focusing on Brazilian sugarcane as its primary feedstock.  According to UNICA, the Brazilian Sugarcane Industry Association, sugarcane is the lowest cost feedstock to produce renewable products at scale and using it enables Amyris to leverage the established Brazilian infrastructure.
  • The firm expects to access feedstock and expand production through a "capital light strategy" with joint ventures with numerous Brazilian sugarcane producers processors.  
  • They plan to commence commercialization starting in 2011 using contract manufacturers, and to have their first capital light production facility, a joint venture with Usina São Martinho, operational in the second quarter of 2012. As they commence commercial production of their initial molecule, farnesene, they expect to target specialty chemical markets. 


Risks

Amyris lists a confidence-sapping set of risks, standard for this type of document, which include:

  • They have a limited operating history and have not generated revenues from the sale of any of their renewable products.  To date, their revenues have consisted of sales of ethanol produced by third parties, funding from third party collaborative research services and government grants.
  • They have no experience producing products at the commercial scale needed for the development of their business, and will not succeed if they cannot effectively scale the technology and processes.
  • The strategy of relying on existing Brazilian sugar and ethanol producers to produce their products makes them substantially dependent on these owners.
  • They may face risks relating to the use of their genetically modified yeast strains including failure to achieve regulatory and public approval.   


Revenue

The company had 2007 sales of $6.1 million, 2008 sales of $13.9 million and 2009 sales of $64.6 million.  The profits from those years were, just kidding -- the company lost $11.7 million, $41.8 million and a whopping $64.4 million in 2009.

Another biotech, company, Codexis, which makes enzymes for fuel production filed its S-1 in December.  Vinod Khosla, an investor in Amyris, has voiced concern that "too many companies have filed and we will get a nanotech moment."  He's "much more concerned about premature IPOs" and cites Codexis as "pretending to be a biofuels company when it is an R&D firm."

How is Amyris any different?

 

(Images from the S-1)





Research news at Cambridge University

Run mouse over list to see previews, click for full article.

European Association of Students & Postdocs in Synthetic Biology (EUSynBioS)

EUSynBioSprelimLogo240The European Association of Students & Postdocs in Synthetic Biology (EUSynBioS) invites you to join its pre-launch community. The EUSynBioS initiative seeks to shape and foster a network of young researchers active the nascent scientific discipline of synthetic biology within the European Union by means of providing an integrative central resource for interaction and professional development.

Key objectives of EUSynBioS include i) the implementation of a central web platform for sharing news and opportunities relevant to members of the community as well as for academic networking, ii) the arrangement and support of events for academic exchange and professional development, iii) liaison with representatives of industry, and iv) establishment of a primary contact for collaboration and exchange with related communities of synthetic biology students and postdocs abroad.

Registering as a member is free and can be completed within 30 seconds via the following link http://www.eusynbios.org/students-and-postdocs/join Students and postdocs who register as a EUSynBioS member will be able to:
o Access a large network of young researchers in synthetic biology for academic collaboration and exchange
o Share technical resources and teaching materials
o Stay informed about relevant events such as conferences, workshops, or social outings o Browse relevant jobs in academia and industry
o Use site visits and mentoring opportunities to interact with prospective employers
o Connect with members of related communities all over the world

By registering as a member prior to the official launch of EUSynBioS, you will not only make a statement of support which will have an impact on the resources available to the community in the future; you will also be given the chance to actively shape EUSynBioS right from the start, and have an edge when applying for a position on the Steering Committee. We are looking forward to your joining us ! Christian Boehm, University of Cambridge.